Subscribe to RSS - BioScrip


BioScrip reports loss in revenues


DENVER – BioScrip reported net revenues of $238.5 million for the first quarter of 2016, compared to $244.4 million for the same period a year ago, a decrease of 2.4%. Adjusted EBITDA was $7.4 millionvs. $4.9 million.

In brief: OIG targets orthotics and vents, Rep. Tipton throws support behind rural providers


WASHINGTON – Orthotics and vents are among the HME that the Office of Inspector General plans to focus on in fiscal year 2016, according to a work plan published week.

BioScrip shows progress


ELMSFORD, N.Y. – BioScrip today reported third quarter revenues from continuing operations of $247.3 million, a 6.8% increase over the same period last year. Gross profit was $63.1 million, a 3.9% increase, and net loss was $24.2 million, the company reported.

Short takes: Salida, RESNA, BioScrip


Salida, Colo.-based Salida Medical & Respiratory has been accredited and certified as a Medicare provider by Community Health Accreditation Partner or CHAP…RESNA seeks volunteer subject matter experts to write new questions for its ATP certification exam.

Short takes: BioScrip, Compression Solutions, Inogen


Elmsford, N.Y.-based BioScrip has extended the expiration date of its offer to exchange up to $200 million in aggregate principal amount of 8.875% senior notes due 2021. The offer will expire on June 16 instead of June 9 at 5 p.m.

BioScrip offers exchange


ELMSFORD, N.Y. – BioScrip is offering to exchange up to $200 million of senior notes due in 2021 for an equal amount of its outstanding senior notes due 2021. The notes are in aggregate principal amount of 8.875%.

BioScrip off to ‘slow start’ in 2015


ELMSFORD, N.Y. – Despite another quarter of double-digit growth for its home infusion biz, BioScrip execs last week expressed “disappointment” that first quarter 2015 results weren’t stronger.

BioScrip reports 10.6% growth in home infusion


ELMSFORD, N.Y. – BioScrip reported revenues of $261.7 million for the first quarter of 2015, a 9.4% increase compared to the same period in 2014. It reported a net loss of $15.9 million vs. $25.3 million.

Short takes: WHILL, BioScrip


WHILL teamed up with Stanford graduate and undergraduate students and Prof.

BioScrip views infusion as ‘growth engine’


ELMSFORD, N.Y. – BioScrip saw double-digit growth in its home infusion business in 2014 and it expects that to continue in 2015, says President and CEO Rick Smith.